A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus

Eli Lilly Japan K.K.0 个研究点目标入组 75 人开始时间: 2018年2月9日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Type 1 diabetes
•Age of 18 to 64 years old
•Have been on multiple daily injection of insulin or continuous subcutaneous insulin infusion therapy for at least one year
•Body mass Index (BMI) of 18.5 to 30.0 kilograms per meter squared (kg/m2)
•Hemoglobin A1c (HbA1c) 10% or less
•Type 2 diabetes
•Age of 20 to 70 years old
•Have been on multiple daily injection of insulin or continuous subcutaneous insulin infusion therapy with/ without oral anti hyperglycemic medications for at least 1 year
•BMI of 18.5 to 35.0 kg/m2
•HbA1c 10% or less

•Have significant changes in insulin regimen and/ or unstable blood sugar control within the past 3 month
•Have received a total daily dose of insulin >1.2 units per kilogram (U/kg)
•Have a history of an episode of severe hypoglycemia in the 1 month prior to screening or have a history of loss of consciousness within the last 2 years induced other than by hypoglycemia
•Have known allergies or sensitivity to LY900018, glucagon, related compounds, or any components of the formulation, or history of significant atopy

发起方